Molecular Therapy · 2020 · 293 citations · 48 references
Life SciencesCell BiologyMolecular BiologyApoptosisGene ExpressionMolecular OncologyApoptosis In CancerApoptosis RegulationApoptotic SignalingBcl-2 Family ProteinsNoncoding Rna BiologyNoncoding Rna In CancerCancer-related Noncoding Rna FunctionIron Regulatory ProteinsLipid Peroxidation MarkersLong Non-coding Rna FunctionLong Noncoding Rna-mediated Apoptosis ControlNoncoding Rna In ApoptosisOxidative Stress In Iron MetabolismSolute Carrier Transporters
Ferroptosis is primarily caused by intracellular iron catalytic activity and lipid peroxidation. The potential interplay between ferroptosis and apoptosis remains poorly understood. Here, we show that the expression of a nuclear long non-coding RNA (lncRNA), LINC00618, is reduced in human leukemia and strongly increased by vincristine (VCR) treatment. Furthermore, LINC00618 promotes apoptosis by increasing the levels of BCL2-Associated X (BAX) and cleavage of caspase-3. LINC00618 also accelerates ferroptosis by increasing the levels of lipid reactive oxygen species (ROS) and iron, two surrogate markers of ferroptosis, and decreasing the expression of solute carrier family 7 member 11 (SLC7A11). Interestingly, VCR-induced ferroptosis and apoptosis are promoted by LINC00618, and LINC00618 accelerates ferroptosis in a manner dependent upon apoptosis. LINC00618 attenuates the expression of lymphoid-specific helicase (LSH), and LSH enhances the transcription of SLC7A11 after the recruitment to the promoter regions of SLC7A11, further inhibiting ferroptosis. Knowledge of these mechanisms demonstrates that lncRNAs related to ferroptosis and apoptosis are critical to leukemogenesis and chemotherapy. Ferroptosis is primarily caused by intracellular iron catalytic activity and lipid peroxidation. The potential interplay between ferroptosis and apoptosis remains poorly understood. Here, we show that the expression of a nuclear long non-coding RNA (lncRNA), LINC00618, is reduced in human leukemia and strongly increased by vincristine (VCR) treatment. Furthermore, LINC00618 promotes apoptosis by increasing the levels of BCL2-Associated X (BAX) and cleavage of caspase-3. LINC00618 also accelerates ferroptosis by increasing the levels of lipid reactive oxygen species (ROS) and iron, two surrogate markers of ferroptosis, and decreasing the expression of solute carrier family 7 member 11 (SLC7A11). Interestingly, VCR-induced ferroptosis and apoptosis are promoted by LINC00618, and LINC00618 accelerates ferroptosis in a manner dependent upon apoptosis. LINC00618 attenuates the expression of lymphoid-specific helicase (LSH), and LSH enhances the transcription of SLC7A11 after the recruitment to the promoter regions of SLC7A11, further inhibiting ferroptosis. Knowledge of these mechanisms demonstrates that lncRNAs related to ferroptosis and apoptosis are critical to leukemogenesis and chemotherapy.
48
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
Kirill Bersuker, Joseph M. Hendricks, Zhipeng Li et al. · Nature · 2019 · 3.6K citations · Full text
Ferroptosis as a p53-mediated activity during tumour suppression
Le Jiang, Ning Kon, Tongyuan Li et al. · Nature · 2015 · 3.4K citations · Full text
Medicine, Cancer Biology, Oncology +14
FSP1 is a glutathione-independent ferroptosis suppressor
Sebastian Doll, Florêncio Porto Freitas, Ron Shah et al. · Nature · 2019 · 3.2K citations · Full text
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Weimin Wang, Michael D. Green, Jae Eun Choi et al. · Nature · 2019 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +16
Imaging individual mRNA molecules using multiple singly labeled probes
Arjun Raj, Patrick van den Bogaard, Scott A. Rifkin et al. · Nature Methods · 2008 · 2.2K citations · Full text